UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 6-K

________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of ~~October~~November 2023

Commission File Number: 001-38281

________________________

PHAXIAM Therapeutics S.A.

(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F S Form 40-F £

INCORPORATION BY REFERENCE

This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-248953 and 333-259690) and registration statements on Form S-8 (File Nos. 333-222673, 333-232670, 333-239429, 333-255900 and 333-265927), of PHAXIAM Therapeutics S.A. (“PHAXIAM” or the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release dated ~~October~~November 2314, 2023

On ~~October~~November 2314, 2023, Phaxiam Therapeutics S.A. issued a press release ~~announcing~~to ~~that~~provide ~~TP ICAP Midcap,~~ a ~~brokerage~~business ~~firm~~ and ~~investment~~financial ~~bank~~update ~~specializing~~for inthe ~~small~~third ~~and~~quarter ~~mid-caps, has initiated coverage~~ of ~~its shares~~2023.

~~Press~~The ~~Release~~full ~~dated~~text ~~October~~of ~~24,~~the ~~2023~~press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

On October 24, 2023, Phaxiam Therapeutics S.A. issued a press release announcing the approval of its phase 1 study clinical design in endocarditis infections caused by Staphylococcus aureus (S. aureus) by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the South-East II-Lyon Ethics Committee (Comité de Protection des Personnes - CPP).EXHIBIT

The full text of the press releases are attached as Exhibit 99.1 and Exhibit 99.2 to this Report on Form 6-K and incorporated herein by reference.


Exhibit						Description

99.1						Press Release dated November 14, 2023.

EXHIBITS

Exhibit						Description
99.1						Press Release dated October 23, 2023.
99.2						Press Release dated October 24, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHAXIAM Therapeutics S.A.

Date:

~~October~~November 2515, 2023

By:

/s/ Eric Soyer

Name Eric Soyer

Title: Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

Filing Compare · PHAXIAM Therapeutics S.A.